Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.34 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.34 |
| ▸ | BTK | Q06187 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17868812 | 0.93 | PARP1 (0.38) | PARP1SLC6A2SLC6A4 | |
| SCHEMBL22611791 | 0.84 | PARP1 (0.40) | PARP1SLC6A2SLC6A4IRAK4RPS6KB1 | |
| SCHEMBL17868824 | 0.80 | PARP1 (0.42) | PARP1BTK | |
| SCHEMBL29057838 | 0.77 | PARP1 (0.38) | PARP1SLC6A2SLC6A4 | |
| SCHEMBL22611822 | 0.75 | PARP1 (0.50) | PARP1SLC6A2SLC6A4SLC6A3IRAK4 | |
| SCHEMBL5808501 | 0.72 | HTR2C (0.44) | PARP1TLR9TLR8TLR7 | |
| SCHEMBL17868822 | 0.71 | PARP1 (0.48) | PARP1SLC6A2SLC6A4SLC6A3RPS6KB1 | |
| SCHEMBL22611651 | 0.71 | PLAT (0.40) | PARP1TLR9TLR8TLR7SLC6A2 | |
| SCHEMBL17868811 | 0.70 | PARP1 (0.45) | PARP1SLC6A2SLC6A4SLC6A3IRAK4 | |
| SCHEMBL22611799 | 0.70 | PARP1 (0.36) | PARP1SLC6A2SLC6A4SLC6A3IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170135994-A9 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20160184282-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160184282-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | PARP1 1174/4885TLR9 3933/4885TLR8 4230/4885 |
| US-20170135994-A9 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | PARP1 1174/4885TLR9 3933/4885TLR8 4230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.